Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant bevacizumab versus observation after resection of high-risk cutaneous melanoma
ISRCTN81261306Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Bevacizumab with Observation (2 arms). Primary endpoint: Overall survival. Started Mar 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on ISRCTN81261306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81261306.